Switch theme
Sign up to access all valuation multiples
SyntekaBio Inc is a bioinformatics venture firm. It is engaged in gene-related research, technology development, and genetic analysis based on the genome big data platform and artificial intelligence deep learning drug development platform. The company manages and analyzes genome analysis and massive biodata and genome.
2009
41
LTM Revenue $1.6M
LTM EBITDA n/a
$82.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SyntekaBio has a last 12-month revenue of $1.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, SyntekaBio achieved revenue of $0.1M and an EBITDA of -$2.0M.
SyntekaBio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SyntekaBio valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.1M | $0.1M | XXX | XXX | XXX |
| Gross Profit | $0.2M | $0.1M | XXX | XXX | XXX |
| Gross Margin | 198% | 102% | XXX | XXX | XXX |
| EBITDA | -$6.3M | -$2.0M | XXX | XXX | XXX |
| EBITDA Margin | -7504% | -2441% | XXX | XXX | XXX |
| Net Profit | -$3.1M | -$7.8M | XXX | XXX | XXX |
| Net Margin | -3652% | -9428% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, SyntekaBio's stock price is KRW 8220 (or $6).
SyntekaBio has current market cap of KRW 125B (or $85.5M), and EV of KRW 121B (or $82.2M).
See SyntekaBio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $82.2M | $85.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, SyntekaBio has market cap of $85.5M and EV of $82.2M.
SyntekaBio's trades at 50.3x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate SyntekaBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for SyntekaBio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $82.2M | XXX | XXX | XXX |
| EV/Revenue | 998.2x | XXX | XXX | XXX |
| EV/EBITDA | -40.9x | XXX | XXX | XXX |
| P/E | -17.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -7.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSyntekaBio's NTM/LTM revenue growth is 345%
SyntekaBio's revenue per employee for the last fiscal year averaged $2K, while opex per employee averaged $0.2M for the same period.
Over next 12 months, SyntekaBio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate SyntekaBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for SyntekaBio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -2441% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -68% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -2095% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $2K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1845% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1137% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2430% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 11905% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| NetraMark | XXX | XXX | XXX | XXX | XXX | XXX |
| Absci | XXX | XXX | XXX | XXX | XXX | XXX |
| Bullfrog AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Immuneering | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SyntekaBio acquired XXX companies to date.
Last acquisition by SyntekaBio was XXXXXXXX, XXXXX XXXXX XXXXXX . SyntekaBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was SyntekaBio founded? | SyntekaBio was founded in 2009. |
| Where is SyntekaBio headquartered? | SyntekaBio is headquartered in South Korea. |
| How many employees does SyntekaBio have? | As of today, SyntekaBio has 41 employees. |
| Is SyntekaBio publicy listed? | Yes, SyntekaBio is a public company listed on KRX. |
| What is the stock symbol of SyntekaBio? | SyntekaBio trades under 226330 ticker. |
| When did SyntekaBio go public? | SyntekaBio went public in 2019. |
| Who are competitors of SyntekaBio? | Similar companies to SyntekaBio include e.g. Benevolent AI, NetraMark, Absci, Bullfrog AI. |
| What is the current market cap of SyntekaBio? | SyntekaBio's current market cap is $85.5M |
| What is the current revenue of SyntekaBio? | SyntekaBio's last 12-month revenue is $1.6M. |
| What is the current EV/Revenue multiple of SyntekaBio? | Current revenue multiple of SyntekaBio is 50.3x. |
| What is the current revenue growth of SyntekaBio? | SyntekaBio revenue growth between 2023 and 2024 was -2%. |
| Is SyntekaBio profitable? | Yes, SyntekaBio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
